Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
about
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repairManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanReversal of target-specific oral anticoagulantsComparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber modelThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literatureDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismSafety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirinRivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitorEvaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulationA novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulantsUtilization and prescribing patterns of direct oral anticoagulants.Latest medical treatment strategies for venous thromboembolism.Design of the rivaroxaban for heparin-induced thrombocytopenia study.Trends in the development of oral anticoagulants.XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Reversal of novel oral anticoagulants in patients with major bleeding.Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorNovel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.Pharmacodynamic and pharmacokinetic basics of rivaroxaban.Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Selecting antithrombotic therapy for patients with atrial fibrillation.Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.Rapid determination of rivaroxaban in human urine and serum using colloidal palladium surface-assisted laser desorption/ionization mass spectrometry.Stroke Prevention in Atrial Fibrillation: Where are We Now?Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.Rivaroxaban in atrial fibrillation.Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban
P2860
Q24187415-816A7E6B-60CF-489F-BA28-8A5A47CB5487Q26766303-A30AF7D2-E1A5-4B29-BAD3-6D0CFC48BFD8Q26828439-FBD257E0-01FC-4DB3-B1CA-F80CF5313BCBQ26828817-2CC746C4-35D0-435F-9F6A-63940DA1D356Q26864411-500309BC-1F87-497E-BEAE-CD3C5860A52CQ27003866-5457567B-3C9D-415A-825C-3D175548DF3BQ27330363-5246652B-6896-4B4E-A025-3135E5F8743CQ27497485-BA13D74F-9A6D-4E42-8EEF-EE30DECE2198Q28079930-BABB51C6-B8D7-49CD-8741-DA68C160036DQ28080616-23CECE26-9FD0-43A6-AD68-4F47F5FEF966Q28087447-71FF4F81-068A-442D-9849-305BBE2F305AQ28200198-FC456D08-6972-4D86-B1F5-16F1231C9568Q28250157-71F991DC-1186-44B8-A33B-05424A0306AEQ28477868-FE851AA6-D49C-4C18-BADD-9265578C3023Q30429127-D14182B6-92A3-49B3-AD1C-3EF3CADE3E78Q30842114-1875C33D-E755-4139-94F6-D4DF67EF05D0Q33375535-9CE9DE73-5865-4B99-9F34-5D101954AD7DQ33413409-41437CC3-BCD8-4B15-B40B-F4640190A09FQ33424198-9615F5A6-943E-495B-8D71-43F560C18DBFQ33997674-0343EBAF-4117-4AEC-9FCE-3B6FF26DD001Q34206252-E4E29FB6-5E9A-48FE-893F-49B2B79D6460Q34252907-E032C4A8-FD04-49E5-9029-ACB486E22D22Q34326655-1F5D1F01-D16A-454E-BFEE-87F652082C97Q34381344-E77AD54B-7EFD-4F6F-803F-E70A467EB463Q34549913-92EF6BFC-5617-4B53-A7CC-B5BD139F509BQ34564159-9927542E-5CC6-4661-BE8C-FA657C539AA5Q34605304-9E544397-32B6-4AFA-8B79-DC58588987D2Q34627624-0656D960-8594-4391-A4DB-99604DF932D8Q34631714-71E44D91-9CA2-4835-8351-D9B332376CE1Q34635335-E943B044-183F-4B5B-A169-A91938413332Q34906214-7A9C85A2-6F3B-404B-BEAC-9845DF83C6EEQ35650380-909364BD-E81E-4271-9FCC-90CED1368CC2Q35684803-3A4D8FCF-EB17-4C29-8157-017D73FC536EQ35768553-DBF2F86B-CAC2-4638-B1B4-C19724BCA860Q35800684-5E3BCDCD-0202-48C0-9F49-9B1C9026751CQ35811581-76FE1440-8F7B-4E81-BB81-03FE18919050Q36087965-200FCC01-5D0A-4B90-9493-1D1949C7FBB4Q36138765-E26DF2FB-74EC-43AE-B0EF-2DE47CFF352EQ36207101-8D49D462-F724-4DEE-87CB-827FE01D87A8Q36241389-8CC86BC7-5F4C-48B3-A4BE-395FA99387F5
P2860
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@ast
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@en
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@nl
type
label
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@ast
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@en
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@nl
prefLabel
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@ast
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@en
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@nl
P2093
P1476
Safety, pharmacodynamics, and ...... l, direct factor Xa inhibitor.
@en
P2093
Barbara Voith
Dagmar Kubitza
Georg Wensing
Michael Becka
Michael Zuehlsdorf
P304
P356
10.1016/J.CLPT.2005.06.011
P407
P577
2005-10-01T00:00:00Z